related_research

HIV Elder Study

The goal of this study is to determine the efficacy of mindfulness based stress reduction (MBSR) to alleviate stress, anxiety and depressive symptoms and improve attention among patients aged 60 or older who suffer from HIV-associated neurocognitive disorders (HAND) and have maximized treatment options.

Summary

Alzheimer’s Disease Trial with Aducanumab

The primary purpose of this study is to find out whether aducanumab has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Biogen
  • Recruiting?: Yes
  • Official study title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Progressive Supranuclear Palsy Trial with C2N-8E12

The primary purpose of this study is to determine the safety, tolerability, and maximally tolerated dosage of C2N-8E12, and anti-tau monoclonal antibody. C2N-8E12 is an immunotherapy (antibody) drug designed to bind to and to remove tau protein. The tau protein is believed to build up to abnormally high levels in the brains of individuals with PSP. This abnormal accumulation is associated with clinical progression of the disease.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: C2N Diagnostics
  • Recruiting?: No
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy

Progressive Supranuclear Palsy Trial with BMS-986168

The primary purpose of this study is to see how safe and well tolerated the study drug BMS-986168 is at different drug amounts in patients with PSP and to measure the amount of study drug in subject’s blood and cerebrospinal fluid (CSF) after taking the drug.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Bristol-Myers Squibb Company (BMS)
  • Recruiting?: Yes
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy (PSP)

Sleep and Cognition in Older Adults

The purpose of this study is to determine how sleep is affected in both healthy aging and neurodegenerative processes. The study aims to determine whether sleep quality alters performance on cognitive tasks in older adults and whether this relationship changes with mild to moderate cognitive impairments.

Summary

  • Study director: Christine Walsh, PhD
  • Sponsor: National Institute of Health (NIH) and the Tau Research Consortium
  • Recruiting?: Yes
  • Official study title: The Relationship Between Sleep and Cognition in Older Adults

Join a Supportive Care Trial

Quality of Life Trials or Supportive Care Trials are research studies to evaluate improving the health, care or quality of life for people, typically without using study drugs or devices. UCSF's Memory and Aging Center (MAC) runs selected supportive trials for people with neurodegenerative disease. Your participation helps us evaluate these interventions. If one of our trials looks interesting to you, please talk with your doctor or contact the study team to see if it is appropriate for you.

Emotion in Parkinson’s Disease

The goal of this study is to learn how Parkinson’s disease affects social and emotional behavior. For example, we aim to assess how participants respond to different kinds of emotional stimuli and whether they can recognize emotions in other people. In addition, we study the emotional behavior of caregivers and their experience of caring for a loved one with Parkinson’s disease.

Participants with Parkinson’s disease who want to volunteer for research on Parkinson’s disease should first join the Parkinson’s Disease Eligibility & Screening Visit. Participating in the eligibility and screening visit involves a single visit to the UCSF Memory and Aging Center and will enable you to potentially get involved in other studies in the Bay Area.

Summary

Molecular Imaging in Parkinson’s Disease

The goal of this study is to learn more about the levels of tau and amyloid proteins in brains of people who have Parkinson’s disease.

Participants with Parkinson’s disease who want to volunteer for research on Parkinson’s disease should first join the Parkinson’s Disease Eligibility & Screening Visit. Participating in the eligibility and screening visit involves a single visit to the UCSF Memory and Aging Center and will enable you to potentially get involved in other studies in the Bay Area.

Summary

Parkinson’s Disease Eligibility & Screening Visit

The Memory and Aging Center is currently recruiting participants with Parkinson’s disease (PD) for involvement in several different research projects at UC San Francisco and UC Berkeley.

Summary

  • Study director: Joel Kramer, PsyD
  • Sponsor: National Institutes of Health (NIH)
  • Recruiting?: Yes
  • Official study title: Parkinson’s Disease Eligibility and Screening
  • Conditions studied: Parkinson's disease (PD)

Purpose of Study

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

The goal of this study is to support the development of FTLD therapies through a multi-site research consortium headquartered at UCSF. The study aims to determine the clinical, genetic, and biomarker profiles of FTLD syndromes where there is a strong correlation between clinical syndrome and underlying pathology (FTD-ALS, PSP, and semantic variant PPA (svPPA)). The study also aims to determine the natural history of familial FTLD using novel clinical measures.

Summary

  • Study directors: Adam Boxer, MD, PhD and Howard Rosen, MD
  • Sponsor: National Institutes of Health (NIH)
  • Recruiting?: Yes
  • Official study title: Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Syndicate content